Literature DB >> 30683704

Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies.

Mathilde Bas1,2,3, Aurélie Terrier1, Emilie Jacque4, Aurélie Dehenne1, Virginie Pochet-Béghin1, Cécile Beghin1, Anne-Sophie Dezetter1, Gilles Dupont1, Anaïs Engrand1, Benjamin Beaufils4, Philippe Mondon1, Nathalie Fournier1, Christophe de Romeuf1, Sylvie Jorieux1, Alexandre Fontayne1, Lennart T Mars2,3, Céline Monnet5.   

Abstract

The long serum t 1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fold increase in serum lifespan. The strongest impact was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn+). Enzymatic desialylation of a Del-FcRn+ mutant or its production in a cell line unable to hypersialylate reduced the in vivo serum t 1/2 of the desialylated mutants to that of native FcRn+ mutants. Consequently, our study proves that sialylation of the N297 sugar moiety has a direct impact on human IgG serum persistence.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30683704     DOI: 10.4049/jimmunol.1800896

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

Review 3.  Sweet Rules: Linking Glycosylation to Antibody Function.

Authors:  Falk Nimmerjahn; Anja Werner
Journal:  Exp Suppl       Date:  2021

Review 4.  Antibody glycosylation in autoimmune diseases.

Authors:  Xing Zhou; Francesca Motta; Carlo Selmi; William M Ridgway; M Eric Gershwin; Weici Zhang
Journal:  Autoimmun Rev       Date:  2021-03-14       Impact factor: 9.754

Review 5.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

Review 6.  Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.

Authors:  David A Spencer; Mariya B Shapiro; Nancy L Haigwood; Ann J Hessell
Journal:  Front Public Health       Date:  2021-05-26

7.  Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex-type N-glycans.

Authors:  Ngan T B Nguyen; Jianer Lin; Shi Jie Tay; Jessna Yeo; Terry Nguyen-Khuong; Yuansheng Yang
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

8.  Engineered Fc-glycosylation switch to eliminate antibody effector function.

Authors:  Qun Zhou; Julie Jaworski; Yanfeng Zhou; Delphine Valente; Joanne Cotton; Denise Honey; Ekaterina Boudanova; Jochen Beninga; Ercole Rao; Ronnie Wei; Christine Mauriac; Clark Pan; Anna Park; Huawei Qiu
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

9.  Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects.

Authors:  Przemyslaw Wielgat; Karol Rogowski; Katarzyna Godlewska; Halina Car
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

Review 10.  Genetic glycoengineering in mammalian cells.

Authors:  Yoshiki Narimatsu; Christian Büll; Yen-Hsi Chen; Hans H Wandall; Zhang Yang; Henrik Clausen
Journal:  J Biol Chem       Date:  2021-02-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.